Abstract
1. Antipneumococcus serum possesses the power of inhibiting for a certain period of time the multiplication of pneumococci. 2. It also has the capacity of inhibiting the proteolytic and glycolytc functions of pneumococci. 3. This power is acquired for the first time or appears in increased amounts in human serum at the time of crisis in lobar pneumonia. 4. The retardation of bacterial growth is thought to be dependent upon the inhibition of metabolic function due to the presence of anti-enzymotic substances in antipneumococcus serum. To this phenomenon we have applied the term antiblastic immunity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
